FY2025 EPS Estimates for Surmodics Increased by Analyst

Surmodics, Inc. (NASDAQ:SRDX) – Research analysts at Zacks Research increased their FY2025 EPS estimates for shares of Surmodics in a research note issued on Monday, November 25th. Zacks Research analyst D. Dey now expects that the company will post earnings per share of $0.14 for the year, up from their previous forecast of $0.13. The consensus estimate for Surmodics’ current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.81 EPS.

Other analysts also recently issued research reports about the stock. StockNews.com initiated coverage on shares of Surmodics in a research report on Saturday. They issued a “hold” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a report on Thursday, November 7th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Performance

NASDAQ SRDX opened at $39.58 on Wednesday. The company has a fifty day simple moving average of $38.50 and a 200 day simple moving average of $39.53. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.14. The company had revenue of $33.23 million during the quarter, compared to the consensus estimate of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%.

Institutional Investors Weigh In On Surmodics

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Surmodics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 865,214 shares of the company’s stock worth $25,385,000 after purchasing an additional 5,927 shares during the period. Renaissance Technologies LLC raised its stake in Surmodics by 5.0% in the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock valued at $25,499,000 after acquiring an additional 28,990 shares during the period. State Street Corp raised its stake in Surmodics by 19.2% in the 3rd quarter. State Street Corp now owns 374,068 shares of the company’s stock valued at $14,506,000 after acquiring an additional 60,240 shares during the period. Gabelli Funds LLC raised its stake in Surmodics by 393.7% in the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company’s stock valued at $10,939,000 after acquiring an additional 207,500 shares during the period. Finally, Gardner Lewis Asset Management L P bought a new stake in Surmodics in the 2nd quarter valued at about $8,531,000. 96.63% of the stock is currently owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).